AR and prostate carcinoma: In fact, AR-Vs are significantly expressed in castration resistant prostate cancer (CRPC) compared to hormone-naive prostate cancer [84], with androgen receptor variant 7 (AR-V7) expressed in 75% of CRPC cases following ADT and less than 1% of primary prostate cancer cases [85].